Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims
Novo Nordisk sued Eli Lilly on Tuesday in U.S. District Court in New Jersey, alleging Lilly's advertising for its GLP-1 drugs is false and misleading.[1]
Novo says Lilly relied on older clinical-trial data to make Lilly's Zepbound and Mounjaro appear more effective than Novo's Wegovy and Ozempic.[1] The complaint alleges Lilly mentions newer FDA-approved higher doses of Wegovy only in small, ambiguous footnotes in its ads.[1] Eli Lilly said its advertisements are truthful, transparent and based on the most direct scientific evidence and vowed to defend the case vigorously.[1]
Wegovy and Ozempic are Novo Nordisk's GLP-1 medicines; Lilly's competing products include Mounjaro and the newer weight-loss drug Zepbound.[1] A June Gallup poll cited in the complaint found 15% of U.S. adults reported using GLP-1 medicines for weight loss, up from 12% the prior year.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On Tuesday, July 21, 2026, Novo Nordisk sued Eli Lilly in U.S. District Court in New Jersey alleging false advertising.
- The suit claims Lilly uses outdated clinical trial data to make Zepbound and Mounjaro appear more effective than Novo’s Wegovy and Ozempic for weight loss and Type 2 diabetes.
- Novo alleges Lilly downplays newer FDA-approved higher doses of Wegovy, mentioning them only in small, ambiguous footnotes in advertisements.
- Eli Lilly responded that its ads are truthful, transparent and based on the most direct scientific evidence, and said it will defend the case vigorously.
- A June Gallup study cited in the article found 15% of U.S. adults report having used GLP-1 medicines for weight loss, up from 12% the prior year.
📰 Source Timeline (1)
Follow how coverage of this story developed over time